title: [PHENOTROPIL AS MODULATOR OF CYTOKINE LEVEL UNDER CONDITIONS OF EXPERIMENTAL IMMUNOPATHOLOGY].
abstract: We have studied the effect of phenotropil on the level of cytokines IL-1, IL-4, and IL-6 under conditions of immunosuppression induced by cyclophosphamide (150 mg/kg, single i.p. injection) and under immune system hyperreactivity caused by lipopolysaccharide (LPS of Pseudomonas aeruginosa, 100 gg/kg, single i.p. injection). The experiments were performed on 48 Wistar male rats aged 6-8 months. Each series was carried out according to similar schedule onree groups of animals: group 1, intact animals; group 2 received cyclophosphamide (series 1) or LPS (series 2); group 3 received phenotropil on the background of immunomodulators. Phenotropil (synthesized at the Department of Organic Chemistry of the A. I. Herzen St. Petersburg Pedagogical University) was administered in a dose of 25 mg/kg (i.p.) for 5 days, starting 2 days before the introduction of immune system activity modulatos. The levels of serum cytokines IL-1β, IL-4, and IL-6 were determined by ELISA "sandwich" with the use of monoclonal antibodies (ELISA kits of BenderMedsystems company; instrument Uniplan AIRF-01 of Picon company, Moscow) at a wavelength of 450 nm. In case of immunodeficiency caused by cyclophosphamide, there was a significant decrease in IL-1β, IL-4 and IL-6, but the introduction of phenotropil largely restored their levels. Upon stimulation with LPS, the immune response showed inc- rease in pro-inflammatory cytokines IL-β, IL-6 and decrease in IL-4. Under these conditions, phenotropil restored the normal levels of IL-1β, IL-6 and caused an increase in the level of IL-4.
authors.forename: I N
authors.initials: IN
authors.lastname: Tyurenkov
authors.forename: M A
authors.initials: MA
authors.lastname: Samotrueva
authors.forename: A A
authors.initials: AA
authors.lastname: Tsibizova
authors.forename: A L
authors.initials: AL
authors.lastname: Yasenyavskaya
mesh_terms: D000818:Animals; D003520:Cyclophosphamide / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004334:Drug Administration Schedule; D007113:Immunity, Innate / Q000187:drug effects; D007155:Immunologic Factors / Q000494:pharmacology*; D007166:Immunosuppressive Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology; D007249:Inflammation / Q000139:chemically induced / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D007274:Injections, Intraperitoneal; D053583:Interleukin-1beta / Q000096:biosynthesis / Q000097:blood*; D015847:Interleukin-4 / Q000096:biosynthesis / Q000097:blood*; D015850:Interleukin-6 / Q000096:biosynthesis / Q000097:blood*; D008070:Lipopolysaccharides; D008297:Male; D010889:Piracetam / Q000031:analogs & derivatives* / Q000494:pharmacology; D011550:Pseudomonas aeruginosa / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D058408:Th1-Th2 Balance / Q000187:drug effects
chemical_list: D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D053583:Interleukin-1beta; D015850:Interleukin-6; D008070:Lipopolysaccharides; D015847:Interleukin-4; C037917:4-phenylpiracetam; D003520:Cyclophosphamide; D010889:Piracetam